Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Anthony Olszanski

Email
Center AffiliationsMolecular Therapeutics

Publications (55) (print view)

no pagination
Loo K, Soliman I, Renzetti M, Li T, Wu H, Reddy S, Olszanski AJ, Farma JM. Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma. J Surg Res. 2020 May 20;254:147-53.
Nakhoda SK, Olszanski AJ. Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceut Med. 2020 Apr;34(2):83-91.
Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. Uveal Melanoma, Version 1.2019 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2020 Feb;18(2):121-31.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230-41.
Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Apr;17(4):367-402.   PMCID: NA
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer discovery. 2019 Mar;9(3):384-95.   PMCID: PMC6397691
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A phase I/IB trial of the vegfr-sparing multikinase ret inhibitor RXDX-105. Cancer discovery. 2019 Jan;9(3):384-95.
Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. Journal for immunotherapy of cancer. 2019 Mar 20;7(1):80.   PMCID: PMC6425606
Moore KN, Bendell JC, LoRusso PM, Olszanski AJ, Zwick-Wallasch E, Jansen M, Vandell AG, Senaldi G. First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. Investigational New Drugs. 2019 Feb;37(1):147-58.
Moore KN, Bendell JC, LoRusso PM, Olszanski AJ, Zwick-Wallasch E, Jansen M, Vandell AG, Senaldi G. First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. Invest New Drugs. 2019 Feb;37(1):147-58.
Olszanski AJ. Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma. J Natl Compr Canc Netw. 2019 May;17(5.5):615-7.
Rogers BB, Cuddahy T, Briscella C, Ross N, Olszanski AJ, Denlinger CS. Oxaliplatin: Detection and Management of Hypersensitivity Reactions. Clinical journal of oncology nursing. 2019 Feb;23(1):68-75.
Shih JC, Olszanski AJ. Orally Administered Cancer Therapy: Breaking Down Barriers to Adherence and Quality of Life. J Natl Compr Canc Netw. 2019 Mar;17(3):290-2.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang YH, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities. Version 1.2019. J Natl Compr Canc Netw. 2019 Mar;17(3):255-89.
Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Oct;25(22):6709-20.
Manley C, Olszanski A. Melanoma in the Bronchus. The New England journal of medicine. 2018 Nov 15;379(20):e36.
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018 Sep 28;:Jco2018789602.   PMCID: PMC6225502
Wagner J, Kline CL, Zhou LL, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation. 2018 Jun;128(6):2325-38.   PMCID: PMC5983321 [Available on 2018-09-01]
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Boyle SM, Ali N, Olszanski AJ, Park DJ, Xiao G, Guy S, Doyle AM. Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. Transplantation proceedings. 2017 Sep;49(7):1551-4.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Anthony Olszanski Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Saturday, August 22, 2020